
Opinion|Videos|January 31, 2025
Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Review highlights gaps in transition from paediatric to adult eye care
2
Beyond anti-VEGF: The next wave in retinal therapy
3
Trehalose-hyaluronate combination aids tear film after eyelid surgery
4
Time is vision: Act fast after ocular chemical burns
5




















